Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

Session I: Surveillance and surgery
Moderator: William J. Catalona, MD

The role of active surveillance for low risk prostate cancer
Laurence Klotz, MD

State-of-the-art radiotherapy: Which type for which patient?
Mack Roach, MD

T3 disease: Is there a role for surgery
Mack Roach, MD
William J. Catalona, MD

PSA only relapse following radical prostatectomy
William J. Catalona, MD

Session II: Challenging cases in prostate cancer I: Prognosis and surgery
Moderator: Mark S. Soloway, MD
Panel: Laurence Klotz, MD, Mack Roach, MD, William J. Catalona, MD

Cases
Mark S. Soloway, MD

Session III: Systemic and radiation therapy
Moderator: Eric J. Small, MD

The best type and timing of androgen deprivation therapies
Charles Ryan, MD

Update: Hormone refractory prostate cancer/chemotherapy in the metastatic setting
Eric J. Small, MD

Side effects of systemic therapy
Charles Ryan, MD

Emerging therapeutic agents in prostate cancer
Eric J. Small, MD

Session IV: Challenging cases in prostate cancer II:
Systemic and radiation therapies
Moderator: Mark S. Soloway, MD
Panel: Charles Ryan, MD, Eric Small, MD, Mack Roach, MD, William J. Catalona, MD

Cases
Mark S. Soloway, MD

Session V: Prognosis and surgery
Moderator: Arthur Sagalowsky, MD

Prognostic and molecular markers: Are they ready for the clinic?
Robert H. Weiss, MD

Laparoscopic approach to small renal masses
Inderbir S. Gill, MD

Alternative approaches to small renal masses: Radiofrequency and cryotherapy ablation
Raymond J. Leveillee, MD

Session VI: Challenging cases in renal cancer I:
Prognosis, surgical and ablative options
Moderator: Mark S. Soloway, MD
Panel: Robert H. Weiss, MD, Inderbir S. Gill, MD, Raymond J. Leveillee, MD

Cases
Mark S. Soloway, MD

Saturday, September 29, 2007

Session VII: Systemic therapy
Moderator: Eric J. Small, MD

Targeted therapies for renal cancer and the role of adjuvant therapy
Robert Dreicer, MD

Emerging therapeutic agents in renal cancer
Robert Dreicer, MD

Session VIII: Challenging cases in renal cancer II:
Implementing new systemic therapies
Moderator: Mark S. Soloway, MD
Panel: Robert Dreicer, MD

Cases
Mark S. Soloway, MD

Session IX: Risk stratification and non-surgical therapies
Moderator: Arthur Sagalowsky, MD

Risk stratification for all patients with bladder cancer
Arthur Sagalowsky, MD

Optimal management of Ta, T1 and CIS bladder cancer using intravesical therapy
Ashish M. Kamat, MD

Options after BCG therapy
Michael O’Donnell, MD

Session X: Challenging cases in stage Ta-T1 bladder cancer
Moderator: Mark S. Soloway, MD
Panel: Arthur Sagalowsky, MD, Ashish M. Kamat, MD

Cases
Mark S. Soloway, MD

Session XI: Surgical, systemic and radiation therapies
Moderator: Gary Steinberg, MD

Debate: Chemotherapy for cT2 – cT3 bladder cancer

Adjuvant chemotherapy post cystectomy
Gary Steinberg, MD

vs.

Neoadjuvant chemotherapy
Mark S. Soloway, MD

Selective bladder preservation: Who, when and why?
John Coen, MD

Emerging therapeutic agents in bladder cancer
Daniel P. Petrylak, MD

Session XII: Challenging cases in stage T2+ bladder cancer
Moderator: Eric J. Small, MD
Panel: Michael O’Donnell, MD, Gary Steinberg, MD, Arthur Sagalowsky, MD, Daniel P. Petrylak, MD (Columbia)

Cases
Eric J. Small, MD

Click here for the CME evaluation / post-test